Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study Neumora Therapeutics, Inc. has initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA…